The launch strengthens Lupin’s presence in the US market and expands its diabetes portfolio, offering a cost-effective alternative for patients requiring combination therapy for blood sugar control.
Pharma major Lupin Ltd on Wednesday announced the launch of its generic version of anti-diabetic medicine dapagliflozin and metformin hydrochloride extended-release tablets in the US following approval by the country's health regulator.
The launched Dapagliflozin and metformin hydrochloride extended-release tablets in the US are of strengths 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg, Lupin said in a regulatory filing.
The launch follows the approval for the company's abbreviated new drug application from the USFDA as bioequivalent to Xigduo XR, the company said.
Published on April 22, 2026
THIS AD SUPPORTS OUR JOURNALISM.
SUBSCRIBE
FOR MINIMAL ADS.
THIS AD SUPPORTS OUR JOURNALISM.
SUBSCRIBE
FOR MINIMAL ADS.
